Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emmaus Life SciencesEMMA -0.22% 3-1 Month Momentum % is 23.96% as of Jul. 23, 2026. The stock has 6 warning signs investors should review. Among 1,389 Biotechnology companies, Emmaus Life Sciences ranks better than 90.64% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-23), Emmaus Life Sciences's 3-1 Month Momentum % is 23.96%.
The industry rank for Emmaus Life Sciences's 3-1 Month Momentum % or its related term are showing as below:
EMMA's 3-1 Month Momentum % is ranked better than 90.64% of 1389
companies
in the Biotechnology industry
Industry Median: -12.73
vs EMMA: 23.96
Emmaus Life Sciences (OTCPK:EMMA) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Emmaus Life Sciences 3-1 Month Momentum % Related Terms
EMMA vs PTIX, BZYR, RMTG: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's 3-1 Month Momentum % falls into.
Emmaus Life Sciences (OTCPK:EMMA) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences (EMMA) has a 3-1 Month Momentum % of 23.96% as of Jul. 23, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #130 out of 1389 companies in the Biotechnology industry, placing it in the top 9.4%.
Is Emmaus Life Sciences' 3-1 Month Momentum % too high?
Emmaus Life Sciences' current 3-1 Month Momentum % is 23.96%. Based on the distribution chart, Emmaus Life Sciences ranks #130 out of 1389 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Emmaus Life Sciences' 3-1 Month Momentum % compare to PTIX and BZYR?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #130 out of 1389 companies for 3-1 Month Momentum %. This places Emmaus Life Sciences in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current 3-1 Month Momentum % is 23.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 17.1% above its estimated fair value. The current 3-1 Month Momentum % is 23.96%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current 3-1 Month Momentum % is 23.96% as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 
